Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: jkrywyn who wrote (12722)	3/14/2014 5:26:05 PM
From: boomertree2	Read Replies (2) \| Respond to of 13111

There are so many factual errors in your historical narrative, that I just don't have the time or patience to correct. You also seem to lose sight of the fact the company belongs to the shareholders and not to management. Further, you state the following "And the fact they were so obliging to return the money says a lot about their character." That is ludicrous. They were forced to return the money due to a stockholders derivative lawsuit, and the settlement avoided continuing litigation and a possible greater damage award. $15 million in alleged excessive compensation is not a small matter to be ignored.....doesn't that also potentially reflect on their character since they paid themselves the bonuses the lawsuit motivated them to return. The settlement is not an admission of guilt. I am a realist and know management won't resign. I hope they hire competent consultants regarding FDA matters and business issues required to maximize shareholder value. I have been long since 2005, and I believe in the drug despite management. I am glad new corporate governance provisions have been instituted to prevent excessive compensation issues in the future. I am willing to chalk up past compensation decisions to poor judgment, and put them in the past. Let's hope management follows the advice of qualified consultants going forward, and a great drug gets approved that can help those suffering from cancer, and the long suffering shareholders can also get relief through a very profitable sale to a pharma company.